BioSpace News Archive

Pomerantz LLP announces that a class action lawsuit has been filed against Nabriva Therapeutics plc and certain of its officers.

Innovent Biologics, Inc. announced that the clinical results of CT103A, the potential best-in-class therapy of fully-human BCMA CAR-T co-developed by Innovent and Nanjing IASO Biotherapeutics, was presented by oral presentation and poster at two of the most prestigious clinical meetings in the worlds of hematology and oncology, the 24th Congress of the European Hematological Society and the American Society of Clinical Oncology Annual Meeting 2019 in Chicago Illinois.

Crescita Therapeutics Inc. announced that it intends to make a normal course issuer bid for a portion of its common shares as appropriate opportunities arise from time to time.

Pomerantz LLP announces that a class action lawsuit has been filed against Heron Therapeutics, Inc. and certain of its officers.

The forty-five-year investigation resulted in arrest after law enforcement’s use of investigative genetic genealogy

Researchers with The Institute of Cancer Research, London, used a modified version of the virus used in the smallpox vaccine—vaccinia—to stimulate the immune system against cancer in laboratory animals with sarcoma.

Pfizer said Array’s pipeline, which includes BRAF/MEK inhibitors, will strengthen its own oncology offerings and provide the opportunity for additional growth.

A report about Amsterdam-based uniQure indicated it is looking at various options, including a potential sale. As a result, company stock jumped as much as 10% in premarket trading.

The lawsuit was joined by Merck, Eli Lilly and Amgen. The companies claim the Department of Health and Human Services does not have the legal authority to force the companies to comply with the new rule.

“Our alliance with Sanofi Genzyme has been foundational for Voyager as we optimized the development of capsids, transgenes and gene therapy delivery,” stated Andre Turenne, president and chief executive officer of Voyager. “We look forward to this new stage of the relationship and to advancing our programs and research efforts for patients with severe neurological diseases.”